Name | Number of supported studies | Average coverage | |
---|---|---|---|
lung | 20 studies | 44% ± 17% | |
brain | 19 studies | 36% ± 16% | |
peripheral blood | 18 studies | 28% ± 7% | |
eye | 10 studies | 53% ± 11% | |
intestine | 9 studies | 32% ± 12% | |
kidney | 9 studies | 33% ± 13% | |
liver | 6 studies | 36% ± 18% | |
adipose | 5 studies | 30% ± 8% | |
pancreas | 4 studies | 49% ± 21% | |
placenta | 4 studies | 57% ± 24% | |
bone marrow | 4 studies | 31% ± 10% | |
uterus | 4 studies | 53% ± 19% | |
breast | 4 studies | 35% ± 7% | |
prostate | 4 studies | 23% ± 6% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
esophagus | 100% | 24356.19 | 1445 / 1445 | 100% | 234.25 | 183 / 183 |
prostate | 100% | 25263.90 | 245 / 245 | 100% | 558.51 | 502 / 502 |
kidney | 100% | 33984.11 | 89 / 89 | 100% | 429.84 | 897 / 901 |
lung | 100% | 45765.29 | 578 / 578 | 99% | 386.82 | 1147 / 1155 |
brain | 99% | 26699.47 | 2624 / 2642 | 100% | 296.01 | 704 / 705 |
thymus | 100% | 53625.52 | 653 / 653 | 99% | 1361.41 | 598 / 605 |
intestine | 100% | 26073.04 | 966 / 966 | 99% | 220.41 | 520 / 527 |
breast | 100% | 30687.59 | 459 / 459 | 98% | 312.71 | 1100 / 1118 |
bladder | 100% | 28401.62 | 21 / 21 | 98% | 281.81 | 495 / 504 |
ovary | 100% | 25213.24 | 180 / 180 | 98% | 230.17 | 420 / 430 |
liver | 100% | 17977.67 | 226 / 226 | 97% | 225.96 | 393 / 406 |
stomach | 100% | 18275.21 | 358 / 359 | 97% | 206.30 | 276 / 286 |
adrenal gland | 100% | 19709.34 | 257 / 258 | 96% | 186.91 | 220 / 230 |
uterus | 100% | 27037.60 | 170 / 170 | 93% | 207.36 | 426 / 459 |
skin | 100% | 24696.51 | 1807 / 1809 | 90% | 191.02 | 424 / 472 |
pancreas | 87% | 8562.42 | 285 / 328 | 98% | 326.19 | 175 / 178 |
adipose | 100% | 32430.55 | 1204 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 48983.80 | 1335 / 1335 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 100% | 146.21 | 1 / 1 |
spleen | 100% | 14005.87 | 240 / 241 | 0% | 0 | 0 / 0 |
heart | 96% | 21511.86 | 829 / 861 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 93% | 136.39 | 42 / 45 |
eye | 0% | 0 | 0 / 0 | 93% | 199.39 | 74 / 80 |
peripheral blood | 80% | 20607.53 | 747 / 929 | 0% | 0 | 0 / 0 |
muscle | 71% | 5389.70 | 568 / 803 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 66% | 76.21 | 19 / 29 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0007409 | Biological process | axonogenesis |
GO_0007186 | Biological process | G protein-coupled receptor signaling pathway |
GO_0007417 | Biological process | central nervous system development |
GO_0031092 | Cellular component | platelet alpha granule membrane |
GO_0005788 | Cellular component | endoplasmic reticulum lumen |
GO_0070062 | Cellular component | extracellular exosome |
GO_0005886 | Cellular component | plasma membrane |
GO_0016020 | Cellular component | membrane |
GO_0005634 | Cellular component | nucleus |
GO_0003677 | Molecular function | DNA binding |
GO_0008201 | Molecular function | heparin binding |
GO_0004867 | Molecular function | serine-type endopeptidase inhibitor activity |
GO_0042802 | Molecular function | identical protein binding |
GO_0046914 | Molecular function | transition metal ion binding |
GO_0005515 | Molecular function | protein binding |
Gene name | APLP2 |
Protein name | Amyloid beta precursor like protein 2 (Amyloid-like protein 2) Amyloid beta precursor like protein 2 (APPH) (Amyloid beta (A4) precursor-like protein 2) (Amyloid protein homolog) (Amyloid-like protein 2) (APLP-2) (CDEI box-binding protein) (CDEBP) (Sperm membrane protein YWK-II) Amyloid beta precursor like protein 2 Alternative protein APLP2 |
Synonyms | APPL2 |
Description | FUNCTION: May play a role in the regulation of hemostasis. The soluble form may have inhibitory properties towards coagulation factors. May interact with cellular G-protein signaling pathways. May bind to the DNA 5'-GTCACATG-3'(CDEI box). Inhibits trypsin, chymotrypsin, plasmin, factor XIA and plasma and glandular kallikrein. Modulates the Cu/Zn nitric oxide-catalyzed autodegradation of GPC1 heparan sulfate side chains in fibroblasts (By similarity). . |
Accessions | ENST00000650012.1 [Q06481-1] E9PSC7 ENST00000278756.7 [Q06481-6] ENST00000533713.5 E9PQS3 ENST00000338167.10 [Q06481-3] Q9UED0 ENST00000528499.5 [Q06481-4] ENST00000345598.9 [Q06481-5] ENST00000533616.5 ENST00000263574.9 [Q06481-1] ENST00000533195.5 Q06481 E9PPD0 L8E7K0 ENST00000530132.5 |